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Analgesic efficacy and safety of morphine in the Procedural 
Pain in Premature Infants (Poppi) study: randomised 
placebo-controlled trial
Caroline Hartley*, Fiona Moultrie*, Amy Hoskin, Gabrielle Green, Vaneesha Monk, Jennifer L Bell, Andrew R King, Miranda Buckle, 
Marianne van der Vaart, Deniz Gursul, Sezgi Goksan, Edmund Juszczak, Jane E Norman, Richard Rogers, Chetan Patel, Eleri Adams, Rebeccah Slater
Summary
Background Infant pain has immediate and long-term effects but is undertreated because of a paucity of evidence-
based analgesics. Although morphine is often used to sedate ventilated infants, its analgesic efficacy is unclear. We 
aimed to establish whether oral morphine could provide effective and safe analgesia in non-ventilated premature 
infants for acute procedural pain.
Methods In this single-centre masked trial, 31 infants at the John Radcliffe Hospital, Oxford, UK, were randomly 
allocated using a web-based facility with a minimisation algorithm to either 100 µg/kg oral morphine sulphate or 
placebo 1 h before a clinically required heel lance and retinopathy of prematurity screening examination, on the same 
occasion. Eligible infants were born prematurely at less than 32 weeks’ gestation or with a birthweight lower than 
1501 g and had a gestational age of 34–42 weeks at the time of the study. The co-primary outcome measures were the 
Premature Infant Pain Profile–Revised (PIPP-R) score after retinopathy of prematurity screening and the magnitude 
of noxious-evoked brain activity after heel lancing. Secondary outcome measures assessed physiological stability and 
safety. This trial is registered with the European Clinical Trials Database (number 2014-003237-25).
Findings Between Oct 30, 2016, and Nov 17, 2017, 15 infants were randomly allocated to morphine and 16 to placebo; 
one infant assigned placebo was withdrawn from the study before monitoring began. The predefined stopping 
boundary was crossed, and trial recruitment stopped because of profound respiratory adverse effects of morphine 
without suggestion of analgesic efficacy. None of the co-primary outcome measures differed significantly between 
groups. PIPP-R score after retinopathy of prematurity screening was mean 11·1 (SD 3·2) with morphine and 
10·5 (3·4) with placebo (mean difference 0·5, 95% CI –2·0 to 3·0; p=0·66). Noxious-evoked brain activity after heel 
lancing was median 0·99 (IQR 0·40–1·56) with morphine and 0·75 (0·33–1·22) with placebo (median difference 
0·25, 95% CI –0·16 to 0·80; p=0·25).
Interpretation Administration of oral morphine (100 μg/kg) to non-ventilated premature infants has the potential for 
harm without analgesic efficacy. We do not recommend oral morphine for retinopathy of prematurity screening and 
strongly advise caution if considering its use for other acute painful procedures in non-ventilated premature infants.
Funding Wellcome Trust and National Institute for Health Research.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Premature infants (born before 37 weeks’ gestation) in 
neonatal intensive care undergo frequent painful pro­
cedures without adequate pain relief.1 Analgesic options 
are limited because few clinical trials have been done in 
infants2 and efficacy and safety data are frequently 
inconclusive.3 Eye examinations to detect retinopathy of 
prematurity—a retinal vascular disorder that can cause 
permanent blindness if untreated4—have reduced signifi­
cantly the risk of visual impairment in premature infants,5 
but this examination is painful, stressful, and causes 
substantial physiological instability for 48 h post pro­
cedure.6–8 Current pain management options—including 
sucrose, local anaesthetic eye drops, breast milk, and 
comfort measures (eg, containment holding)—are 
effective for minor procedures but are not thought to 
provide adequate pain relief for retinopathy of prematurity 
screening9 and do not prevent the physiological instability 
caused by the pro cedure.8 An analgesic is needed that can 
be administered safely to provide effective procedural pain 
relief to pre mature infants, regardless of intravenous 
access, care setting, or ventilatory status.
Intravenous morphine is frequently used for sedation 
during invasive ventilation in neonates, but evidence for its 
analgesic efficacy remains contradictory and inconclusive.3 
Pain assessment is challenging in the absence of verbal 
report, and composite behavioural and physiological pain 
scores have formed the cornerstone of infant pain 
assessment.10 Recently, neurophysiological measures have 
been developed to objectively quantify pain­related brain 
activity and reflex activity; these measures have been well 
characterised after heel lancing.11,12
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We studied infants who required both a routine blood 
test and retinopathy of prematurity screening on the same 
morning. We aimed to test whether one dose of oral 
morphine sulphate (100 μg/kg) administered to non­
ventilated premature infants before heel lancing and 
retinopathy of prematurity screening would provide 
analgesia, reduce physiological instability, and be safe.13 
We chose an oral dose of 100 μg/kg (with an estimated 
peak effect at 1 h)14 based on extrapolation from guidance 
in the British National Formulary for children, local 
practice guidelines for neonatal eye surgery, and findings 
of a previous incomplete trial.15 We assessed multimodal 
pain measures: noxious­evoked brain acti vity, reflex 
activity, physiology, and behaviour. To provide insights 
into how both morphine and retinopathy of prematurity 
screening alter infant physiology, we monitored infants’ 
heart rate, respiratory rate, blood pressure, and oxygen 
satura tion for 24 h before and after the clinical procedure. 
We evaluated drug safety by assessing the incidence of 
hypotension requiring ionotropes and of apnoeic episodes 
requiring resuscitative non­invasive positive pressure 
ventilation (NIPPV), both potential adverse effects of 
morphine.16
Methods
Study design and participants
We undertook a single­centre, masked, randomised, 
placebo­controlled trial at the Newborn Care Unit at the 
John Radcliffe Hospital (Oxford University Hospitals 
NHS Trust, Oxford, UK). This trial was supported by the 
National Perinatal Epidemiology Unit Clinical Trials 
Unit (NPEU CTU).
Each infant was studied on a single test occasion. 
Infants were eligible for inclusion if they were born 
prematurely at less than 32 weeks’ gestation or with a 
birthweight less than 1501 g (fulfilling UK retinopathy of 
prematurity guidelines),17 were both inpatients at the 
time of the study and aged 34–42 weeks’ gestation, and 
required a heel lance and retinopathy of prematurity 
screening on the same test occasion (referred to hereafter 
as the clinical procedure). Exclusion criteria are provided 
in the appendix. All infants were assessed for eligibility 
by a senior clinician. We reassessed eligibility at random­
is ation, study commencement, and before administration 
of morphine or placebo.
We obtained written informed parental consent for all 
infants. Approval was obtained from the Medicines and 
Healthcare products Regulatory Agency (MHRA) and 
Northampton Research Ethics Committee (15/EM/0310). 
This trial conformed to the standards set by the Declaration 
of Helsinki. 
Randomisation and masking
We randomised infants to receive either morphine 
or placebo, using a web­based facility hosted by the 
NPEU CTU, with a minimisation algorithm to ensure 
Research in context
Evidence before this study
Morphine is one of the most frequently prescribed analgesics 
in neonatal practice. Although evidence suggests that 
intravenous morphine provides sedation in ventilated infants, 
and some research suggests it might provide effective 
analgesia for acute painful procedures (eg, chest drain 
insertion and central line placement), differences in study 
designs, dosing, heterogeneity of outcome measures, and 
administration of rescue boluses have made interpretation of 
the evidence challenging. A Cochrane review reported that 
evidence is insufficient to recommend routine clinical use of 
morphine for procedural pain relief in ventilated infants. Many 
neonatal formularies include oral morphine as a treatment for 
pain in neonates, and suggested doses are 50–200 μg/kg. 
A previous pilot study investigated the analgesic efficacy of 
oral morphine before retinopathy of prematurity screening, 
but findings were inconclusive because the study was stopped 
early owing to changes in Medicines and Healthcare products 
Regulatory Agency regulations.
Added value of this study
In this study, 100 μg/kg oral morphine was administered to 
non-ventilated infants before retinopathy of prematurity 
screening and clinical heel lancing. Multiple modalities were 
used to quantify analgesic efficacy, which included changes in 
pain scores, noxious-evoked brain activity, and reflex 
withdrawal activity. A comprehensive approach was used to 
assess changes in oxygen saturation, respiratory rate, heart 
rate, and ventilation requirement in the 24 h period before 
and after the clinical procedures. In our study, administration 
of 100 μg/kg oral morphine in non-ventilated premature 
infants had profound respiratory adverse effects without 
suggestion of analgesic efficacy.
Implications of all the available evidence
We do not recommend the use of oral morphine at a dose of 
100 μg/kg in non-ventilated premature infants for 
retinopathy of prematurity screening. Morphine produces 
cardiorespiratory effects that last for an average of 6–8 h. 
If this dose or a greater dose of morphine were to be 
administered to infants for other clinical indications or in 
future clinical trials, the infant should be monitored 
continuously and clinicians should expect that these infants 
might require a substantial increase in respiratory support or 
resuscitation. Thus, morphine should not be administered 
unless resuscitative equipment is available immediately, staff 
are trained appropriately, and both the risks and potential 
benefits are considered carefully. Difficulties in measuring 
infant pain are widely recognised, and the methodology used 
in our trial to measure both analgesic efficacy and side-effects 
of a pharmacological intervention sets new standards for the 
conduct of clinical trials of analgesics in infants.
For the British National 
Formulary for children see 
https://bnfc.nice.org.uk
See Online for appendix
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approximate balance of key demographics between the 
groups (gestational age at birth, gestational age at time of 
randomisation, intrauterine growth restriction, time on 
ventilation, time since morphine last given, presence of a 
gastric tube, and history of surgery). Morphine sulphate 
(at a concentration of 200 µg/mL) and placebo solutions 
were indistinguishable by colour, odour, and flow, and 
were dispensed in 10 mL glass amber bottles with tamper­
evident caps and a pack identification label (appendix). 
Researchers, clinicians, outcome assessors, and parents 
were masked to treatment allocation. In the event of an 
emergency, treatment allocation could be unmasked by 
a member of the clinical team using a single­use 
access code on the randomisation website. In the event of 
an infant becoming ineligible after randomisation, the 
study was postponed and recommenced when the infant 
became eligible, without rerandomisation.
Procedures
A study timeline is provided in the appendix. Continuous 
electronic data capture of heart rate, respiratory rate, and 
oxygen saturation began app roxi mately 24 h before 
the clinical procedure to establish a baseline of clinical 
stability for every infant. We recorded all changes in 
oxygen requirement, and measured blood pressure 
every 6 h.
Approximately 60 min before the clinical procedure, 
we gave infants one dose of either morphine sulphate 
(100 µg/kg) or placebo (of equivalent volume). We 
calculated the volume of the dose using the infant’s 
working weight (the most recent weight in the 
infant’s medical notes and used on their current drug 
prescription chart). We administered the dose orally 
(via syringe) or via a nasogastric tube (flushed with 
aspirate). Mydriatic eye drops (tropicamide 1% and 
phenylephrine 2·5%) were administered at 60 min and 
again at 45 min before the clinical procedure. 
Electroencephalography (EEG) and electromyography 
(EMG) electrodes were then sited, as described in the 
appendix.
Shortly before the clinical procedure, we swaddled the 
infant (to provide non­pharmacological pain relief), began 
video monitoring, and did a control heel lance (lancet was 
rotated and held against the foot, with the blade released 
into the air). This procedure was followed by the clinically 
required heel lance, approximately 60 min post admini­
stration of morphine or placebo. No non­essential or 
additional blood tests were done. After the heel lance and 
blood collection, we ensured that infants were fully settled 
and did not exhibit behavioural or physiological signs of 
distress before the retinopathy of prematurity examination. 
A senior opthalmologist performed all retinopathy of 
prematurity examinations. Topical local anaes thetic 
(proxymetacaine 0·5%) eye drops were instilled before 
insertion of an eyelid speculum, and binocular indirect 
ophthalmoscopic examination was completed using a 
Flynn style indenter. 
After the clinical procedure, EEG and EMG leads were 
removed and physiological recordings and documentation 
of oxygen requirements continued for 24 h. A skilled 
neonatal nurse or paediatric doctor from the research 
team remained present for a minimum of 6 h after drug 
administration. 
Outcomes
The co­primary outcome measures were a behavioural 
pain score calculated after retinopathy of prematurity 
screening using the Premature Infant Pain Profile–
Revised (PIPP­R),18 and the magnitude of noxious­evoked 
brain activity in response to heel lancing, measured using 
Figure 1: Trial profile
EEG=electroencephalography. EMG=electromyography. PIPP-R=Premature Infant Pain Profile–Revised. 
ROP=retinopathy of prematurity. *One excluded because of artifact.
276 infants assessed for eligibility
95 approached for inclusion
36 enrolled
31 randomised
181 ineligible
120 discharged before approach
1 discharged from ROP screening before approach
31 died
29 inclusion criteria not met
59 did not consent
45 declined consent
10 discharged after initial approach
4 discharged from ROP screening after approach
5 not randomised
2 became ineligible
3 discharged
15 assigned morphine
0 withdrawals
16 assigned placebo
15 received morphine 15 received placebo
15 included in PIPP-R 
analysis
15 included in EEG analysis
15 included in EMG analysis
15 included in PIPP-R 
analysis
14 included in EEG analysis*
14 included in EMG 
analysis*
1 did not receive placebo   
(withdrawn by parental request   
before study commenced 
because of imminent discharge)
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a validated EEG template (appendix).11 We calculated the 
PIPP­R score in the 30 s period after retinopathy of 
prematurity screening (after removal of the speculum 
following examination of the second eye). A PIPP­R score 
of 6 or lower indicates little or no pain and a score greater 
than 12 indicates moderate­to­severe pain.19
Secondary outcome measures were reflex withdrawal 
and the PIPP­R score after heel lancing (appendix). To 
assess the nociceptive specificity of outcome measures, 
we also assessed the PIPP­R score, magnitude of 
noxious­evoked brain activity, and reflex withdrawal for 
the control heel lance. Background brain activity and 
reflex withdrawal activity were also assessed in a 
baseline period during which the infant’s foot was 
gently held but no stimuli were applied.
We assessed the clinical stability of infants by 
considering episodes of oxygen desaturation, brady­
cardia, tachy cardia, and apnoea, and requirements for 
an increase in respiratory support, during the 6 h and 
24 h periods after the clinical procedure, which were also 
secondary outcomes of the study. Episodes of oxygen 
desaturation were identified from the periph eral 
oxygen saturation signal as periods during which oxygen 
saturation fell below 80% for at least 10 s. Episodes of 
bradycardia were identified as periods during which the 
heart rate fell below 100 beats per min (bpm) for at least 
15 s. Episodes of tachycardia were defined as periods 
during which the heart rate was greater than 200 bpm 
for at least 15 s (appendix). Apnoeic episodes were 
identified from clinical records or by retrospective review 
of the impedance pneumo graph for breathing pauses 
longer than 20 s during bradycardic episodes (appendix). 
Increases in respiratory support were defined as a 
significant increase in oxygen requirement or an 
increase in respiratory support modality (appendix).
We assessed drug safety by calculating the incidence 
of apnoea requiring NIPPV and the incidence of hypo­
tension requiring ionotropes in the 24 h period post 
administration of morphine or placebo. Clinicians on 
the research team recorded a description of adverse 
events that occurred in the 24 h period post 
administration of morphine or placebo, including 
action taken, severity, and causality of the event, 
identified by consultation of the clinical team and 
review of clinical records (appendix). All serious adverse 
events were reviewed by the Data Monitoring 
Committee.
Statistical analysis
We calculated that a sample size of 132 infants would 
allow detection of a clinically meaningful reduction in 
pain scores (a clinically significant reduction in PIPP­R 
scores was defined as 2 points),13 from a conservative 
post­retinopathy of prematurity screening mean 
PIPP­R score of 8·3 (SD 3·5) from a previous study,20 
with power of 90% (p<0·05; two­tailed). We considered 
a 40% reduct ion in noxious­evoked brain activity 
clinically meaning ful, since a similar re duction in 
adults corres ponds to significantly lower verbally 
reported pain scores.21 A sample size of 132 infants was 
also required for this co­primary outcome measure, 
with power of 90% (p<0·05; two­tailed). We inflated the 
sample size to 156 infants (78 per arm) to account for 
Morphine (n=15) Placebo (n=15)
Characteristics at birth
Gestational age (weeks)*† 28·1 (26·3–30·1) 28·6 (27·9–29·7)
Birthweight (g) 1107 (329) 1173 (350)
Birthweight Z-score –0·4 (0·9) –0·2 (1·0)
Intrauterine growth 
restriction*
2 (13%) 3 (20%)
Apgar score at 10 min‡ 10·0 (9·0–10·0) 10·0 (8·0–10·0)
Mode of delivery
Spontaneous vaginal delivery 8 (53%) 5 (33%)
Caesarean section 7 (47%) 10 (67%)
Male sex 12 (80%) 8 (53%)
Female sex 3 (20%) 7 (47%)
Multiple pregnancy 4 (27%) 4 (27%)
Characteristics at time of randomisation
Gestational age (weeks)*† 34·7 (34·1–35·1) 34·7 (34·1–35·1)
Time on ventilation (days)*§ 8·0 (1·0–20·0) 3·5 (2·0–19·5)
Time since morphine last 
given (days)*¶
46·5 (33·5–49·0) 19·0 (15·0–39·0)
Presence of gastric tube* 14 (93%) 15 (100%)
Intraventricular haemorrhage 
(grade I or II)
3 (20%) 2 (13%)
History of surgery* 0 (0%) 1 (7%)
Characteristics at time of clinical procedure
Gestational age (weeks)† 35·0 (34·3–35·4) 34·9 (34·3–36·3)
Postnatal age (days) 50 (28–58) 49 (43–59)
Weight (g) 2049 (426) 2127 (331)
Duration of ROP screening (s) 97 (82–108) 91 (83–110)
Diagnosis of ROP 2 (13%) 2 (13%)
Level of care
Intensive care unit 1 (7%) 1 (7%)
High-dependency unit 5 (33%) 9 (60%)
Low-dependency unit 9 (60%) 5 (33%)
Respiratory support modality
Self-ventilating 9 (60%) 8 (53%)
Low-flow oxygen therapy 2 (13%) 1 (7%)
High-flow oxygen therapy 4 (27%) 6 (40%)
Time between IMP 
administration and heel lance 
(min)
61 (57–66) 63 (58–70)
Data are median (IQR), mean (SD), or number (%). IMP=investigational medicinal 
product. ROP=retinopathy of prematurity. *Criteria used in minimisation 
algorithm for randomisation. †Postmenstrual age is often used in neonatal 
practice. In our unit, the infants’ gestational age is recorded each day in the 
medical and nursing notes; therefore, we have used this nomenclature. ‡Data are 
for 15 infants in the morphine group and 13 in the placebo group. §Data are for 
six infants in the morphine group and 12 in the placebo group. ¶Data are for four 
infants in the morphine group who previously received morphine and seven in 
the placebo group.
Table 1: Infant demographics
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multiple births (assuming a 25% rate and an intra­
cluster correlation coefficient of 0·5) and 10% loss to 
follow­up.
Trial outcomes were analysed and reported according 
to the trial protocol (version 6.0) and statistical analysis 
plan (version 2.0). Changes to the protocol (because of 
early trial cessation) are listed in the statistical analysis 
plan and the appendix. Analysis was per protocol, and 
a p value of 0·05 (two­sided 5% significance level) was 
deemed significant for all outcome measures.
We reported mean (SD) or median (IQR) values 
according to whether data were normally distributed or 
skewed. We calculated mean or median differences with 
95% CIs and p values. We compared PIPP­R scores 
between groups using t tests. The magnitude of noxious­
evoked brain activity and reflex withdrawal activity were 
compared between groups using a Wilcoxon rank­sum 
test, with the Hodges­Lehmann estimator used to calculate 
median differences with 95% CIs. We calculated SE of the 
median using bootstrap sampling. We assessed inter­rater 
and intra­rater reliabi lity of PIPP­R scoring using intra­
class correlation from a random­effects model with 
95% CIs. Intra­rater reliability was 0·98 (95% CI 
0·97–0·99) for heel lance PIPP­R scores and 0·97 
(0·94–0·99) for retinopathy of prematurity screening. 
Inter­rater reliability was 0·98 (0·95–0·99) for heel lance 
and 0·89 (0·79–0·95) for retinopathy of prematurity 
screening.
For episodes of bradycardia, tachycardia, and oxygen 
desaturation, we standardised the difference in counts 
in the 6 h and 24 h periods before and after the clinical 
procedure, to adjust for the number of pre procedure 
episodes for every infant. We defined the standardised 
difference in number of episodes in the periods before 
and after the clinical procedure as the difference in 
number of episodes, as a proportion of the total number 
of episodes, for every infant, symmetrically in both the 
6 h and 24 h periods (eg, in the 24 h period post 
procedure relative to the 24 h period preprocedure). To 
avoid issues caused by zero counts, we added a negligible 
constant term (0·01) to each count before standardisation. 
We compared standardised differences between treat­
ment groups using a Wilcoxon rank­sum test, with the 
Hodges­Lehmann estimator used to calculate median 
Figure 2: Example of data recorded in an infant assigned morphine
48 h records of heart rate, oxygen saturation, and mean blood pressure every 6 h are shown for the 24 h periods before and after the clinical procedure. Episodes of 
tachycardia, bradycardia, oxygen desaturation, and apnoea are identified (red vertical lines). The reflex withdrawal activity, EEG activity, and change in heart rate and 
oxygen saturation are shown in the 10 s before and after the heel lance. The noxious-evoked brain activity template is projected onto the EEG trace (overlaid in red). 
The time of drug administration is indicated by the green vertical line (approximately 1 h before the clinical procedure). This infant was chosen as a representative 
example because he had all clinical stability events (tachycardia, bradycardia, oxygen desaturation, and apnoea) and had clear changes in reflex withdrawal, brain 
activity, and physiology to the heel lance. Traces of noxious-evoked brain activity to the heel lance and 48 h physiological traces for all individual infants are in the 
appendix. bpm=beats per min. EEG=electroencephalogram.
Oxygen 
saturation
Desaturation
Apnoea
Heart rate
Tachycardia
Bradycardia
0
Time (h)
Time (s)
2418126−6−12−18−24
Mean blood
pressure
60 mm Hg
40 mm Hg
100%
200 bpm
100 bpm
60%
100 µV
100 µV
3%
Change in heart rate 
Change in oxygen 
saturation
Reflex withdrawal
EEG
Noxious-evoked
brain activity
0–5 5 10–10
50 µV
500 ms
For the trial protocol and 
statistical analysis plan see 
https://www.npeu.ox.ac.uk/
poppi/protocol-publications
Articles
2600 www.thelancet.com   Vol 392   December 15, 2018
differences with 95% CIs. Infants with new­onset 
apnoea or an increased number of apnoeic episodes 
after the clinical pro cedure were compared using 
risk ratios (RRs). The number of infants requiring in­
creased respir atory support after the clinical procedure 
was compared using risk differences (although we 
planned to use RR analysis according to the statistical 
analysis plan, this could not be done because no infants 
in the placebo group needed increased respiratory 
support). In a post­hoc analysis, we calculated the 
average time courses of physi ologi cal variables (heart 
rate, respiratory rate, and oxygen saturation) over the 
48 h trial period and compared them between groups 
using non­parametric cluster analysis (appendix). We 
analysed data with Stata SE (version 13.1) and MATLAB 
(R2017a), and East (version 6.4) was used for the 
stopping boundary and safety analysis.
A trial stopping boundary was predefined based on the 
event rate of apnoeic episodes requiring resuscitative 
NIPPV (bag valve mask [visionary single patient use 
manual resuscitator; Marshall Airway Products, Radstock, 
UK] or Neopuff [Fisher & Paykel Healthcare, Auckland, 
New Zealand]). The boundary was chosen by the Data 
Monitoring Committee before any analyses, after 
review of hypothetical trial scenarios and defined using a 
group sequential method with a one­sided gamma 
spending function (γ=4·5, type I error rate=0·2, estimated 
power=0·79). The selected boundary was based on a 
control group event rate of 7% and a difference between 
the group event rates of 12%. After 25 infants were 
randomised and studied, the Data Monitoring Committee 
convened for a safety review as planned and were 
provided with the stopping boundary graph, clinical 
stability and safety data summarised by arm, and detailed 
summaries of safety and adverse events, to consider 
evidence for benefit and harms.
This trial is registered with the European Clinical Trials 
Database (number 2014­003237­25).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between Oct 30, 2016, and Nov 17, 2017, 31 infants aged 
34–39 weeks’ gestation (at the time of the study), who 
required retinopathy of prematurity screening and 
heel lancing on the same occasion, were enrolled and 
randomly assigned either 100 μg/kg of oral morphine 
(n=15) or placebo (n=16); one infant assigned placebo was 
withdrawn from the study before monitoring began 
(figure 1).
The Data Monitoring Committee reviewed safety data 
after recruitment of 25 infants (on Dec 4, 2017), and 
the predefined stopping boundary had been crossed. The 
Data Monitoring Committee requested data for all 
31 infants who had been randomised. They concluded 
there was sufficient evidence to suggest that oral mor­
phine at the dose used in our study has the potential to 
cause harm without any suggestion of analgesic benefit. 
After con sidering the evidence and wider implications, 
the Trial Steering Committee concluded that the trial 
should not continue in its present form and recom­
mended that the investigators review the data to guide 
Figure 3: Co-primary and secondary outcome measures of analgesic efficacy 
Co-primary outcomes are shown in (A) and (B). (A) Mean (SE) PIPP-R scores after ROP screening. (B) Median (SE) 
magnitude of noxious-evoked brain activity after heel lance. The (Woody) filtered EEG is shown overlaid with the 
template of noxious-evoked brain activity (in red). Secondary outcomes are shown in (C) and (D). (C) Mean (SE) 
PIPP-R score after heel lance. (D) Median (SE) magnitude of reflex withdrawal activity after heel lance. Magnitude 
is quantified using RMS in 250 ms windows. EEG=electroencephalogram. EMG=electromyography. 
PIPP-R=Premature Infant Pain Profile-Revised. RMS=root-mean-square. ROP=retinopathy of prematurity.
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Morphine Placebo Median difference 
(95% CI)
p value
6 h
Oxygen desaturation 0·57 (0·00 to 0·99) –0·06 (–0·65 to 0·00) 0·66 (0·36 to 1·00) 0·0007
Bradycardia 0·50 (0·00 to 0·99) 0·00 (0·00 to 0·98) 0·33 (0·00 to 0·98) 0·07
Tachycardia 0·00 (0·00 to 0·00) 0·00 (0·00 to 0·00) 0·00 (–0·16 to 0·00) 0·32
24 h
Oxygen desaturation 0·22 (–0·02 to 0·98) 0·00 (–0·25 to 0·08) 0·33 (0·03 to 0·75) 0·019
Bradycardia 0·43 (0·00 to 1·00) 0·00 (–0·50 to 0·60) 0·43 (0·00 to 1·00) 0·019
Tachycardia 0·00 (–0·50 to 0·98) 0·00 (0·00 to 0·00) 0·00 (–0·38 to 0·98) 0·57
Data are median (IQR) of the standardised difference in number of episodes before and after intervention, unless 
otherwise stated.
Table 2: Clinical stability
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further investigation. The trial was stopped by the 
Central Monitoring Team on March 15, 2018 (appendix).
There were no deviations from exclusion or inclusion 
criteria. Infant demographics and clinical characteristics 
at birth and at the time of intervention are reported in 
table 1 according to group allocation. Most baseline 
characteristics were well balanced between treatment 
groups; however, a few variables were less well balanced 
(eg, the number of infants who required ventilatory 
support), which is expected in view of the small sample 
size. Figure 2 shows example data for one infant for each 
recording modality.
The co­primary outcome measures used to assess 
morphine analgesic efficacy were PIPP­R score after 
retinopathy of prematurity screening and magnitude of 
noxious­evoked brain activity after heel lancing. PIPP­R 
scores after retinopathy of prematurity screening did not 
differ significantly between infants assigned morphine 
(mean 11·1 [SD 3·2]) and those allocated placebo 
(10·5 [3·4]; mean difference 0·5, 95% CI –2·0 to 3·0; 
p=0·66; figure 3). Similarly, the magnitude of noxious­
evoked brain activity after heel lancing did not differ 
significantly between infants assigned morphine 
(median 0·99 [IQR 0·40–1·56]) and those allocated 
placebo (0·75 [0·33–1·22]; median difference 0·25, 
95% CI –0·16 to 0·80; p=0·25; figure 3). EEG responses 
for all individual infants are shown in the appendix. The 
secondary outcome measures of PIPP­R score after the 
heel lance and the magnitude of reflex withdrawal activity 
evoked by the heel lance did not differ between the 
two groups. Mean PIPP­R score after heel lance was 
7·9 (SD 3·4) with morphine and 8·5 (3·9) with placebo 
(mean difference –0·6, 95% CI –3·3 to 2·1; p=0·66). 
The magnitude of reflex withdrawal was median 
24·8 (IQR 19·7–44·8) with morphine and 12·4 (6·1–46·3) 
with placebo (median difference 8·9, 95% CI –12·0 to 
22·4; p=0·48; figure 3). The magnitude of each pain­
related outcome measure increased significantly after the 
clinical procedure compared with control stimuli and 
non­noxious background activity (appendix), showing 
that the measures were discriminative and appropriate 
for assessing analgesic efficacy in this population.
The clinical stability of each infant was assessed over 
48 h (24 h before and after the clinical procedure). Infants 
assigned morphine had significantly more episodes of 
oxygen desaturation in the 6 h and 24 h periods after the 
clinical procedure, and significantly more episodes of 
bradycardia in the 24 h period after the clinical procedure, 
compared with those allocated placebo (table 2; figure 4). 
There were no differences in the number of episodes of 
tachycardia.
Eight (53%) of 15 infants who received morphine 
developed new­onset apnoea or an increase in the number 
of apnoeic episodes in the 24 h period after the clinical 
Figure 4: Assessments of physiological stability
(A) Median (SE) of the standardised difference in number of episodes of desaturation in the 6 h period after the clinical procedure compared with the 6 h period 
before. (B) Median (SE) of the standardised difference in number of episodes of desaturation in the 24 h period after the clinical procedure compared with the 24 h 
period before. (C) Median (SE) of the standardised difference in number of episodes of bradycardia in the 6 h period after the clinical procedure compared with the 6 h 
period before. (D) Median (SE) of the standardised difference in number of episodes of bradycardia in the 24 h period after the clinical procedure compared with the 
24 h period before. (E) Mean (SE) heart rate during the 48 h monitoring period. (F) Mean (SE) respiratory rate during the 48 h monitoring period. (G) Mean (SE) 
oxygen saturation during the 48 h monitoring period. (E–G) Individual infant traces are baseline-corrected to the average baseline across all infants. Time zero is the 
point of the clinical procedure. Grey vertical dashed line indicates the time of administration of morphine or placebo. Grey boxes indicate periods during which the 
treatment groups differed significantly. *p=0·0007. †p=0·019.
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procedure, compared with three (20%) of 15 infants who 
received placebo (RR 2·7, 95% CI 0·9–8·2; p=0·085). 
More infants assigned morphine had new­onset or 
increased apnoea in the 6 h period after the clinical 
procedure compared with those allocated placebo 
(seven of 15 infants vs three of 15 infants), although the 
difference was not significant (RR 2·3, 95% CI 0·7–7·4; 
p=0·15). Significantly more infants allocated morphine 
required an increase in respiratory support in the 6 h 
period after the clinical procedure compared with those 
assigned placebo (four of 15 infants vs none of 15 infants; 
risk difference 0·3, 95% CI 0·0–0·5; p=0·020), and in the 
24 h period after the clinical procedure (five of 15 infants 
vs none of 15 infants; risk difference 0·3, 95% CI 0·1–0·6; 
p=0·006).
Drug safety was assessed by considering the number of 
infants who had apnoeic episodes requiring resuscitation 
with NIPPV and the incidence of hypotension requiring 
treatment with inotropes in the 24 h period after drug 
administration. The predefined safety stopping bound­
ary was passed, because three (20%) of 15 infants assigned 
morphine had apnoeic episodes requiring resuscitation 
with NIPPV in the 24 h period after drug administra tion, 
compared with no infants assigned placebo (differ­
ence in pro portion 0·2, 80% CI [adjusted to allow 
for planned multiple analyses] 0·05–1·00; p=0·085; 
signifi cant at the 20% level allowing for the prespecified 
stopping boundary). No infant needed inotropes. Blood 
pres sure was similar in infants in both treatment groups 
(appendix).
11 (37%) of the 30 infants had adverse events, two of 
whom had unforeseeable serious adverse events (table 3). 
Eight (53%) of the 15 infants who received morphine 
had respiratory adverse events attributed as possibly or 
probably related to drug administration. Of the 15 infants 
who received placebo, one had a mild respiratory ad­
verse event. Two infants in each treatment group were 
diagnosed with retinopathy of prematurity, an expected 
foreseeable serious adverse event.
Post­hoc exploratory analyses showed that administra­
tion of morphine resulted in a significant reduction in 
heart rate and respiratory rate compared with placebo. 
Morphine administration reduced the group average 
heart rate by a maximum of 13·9 bpm at 1·5 h after the 
clinical procedure (ie, approximately 2·5 h after drug 
administra tion), and heart rate was significantly lower in 
infants allocated morphine for 6 h (from 0·5 h to 6·5 h 
after the clinical procedure; p=0·0001; figure 4). The 
respira tory rate dropped by an average of eight breaths 
per min at 1·5 h after the clinical procedure, and it was 
significantly lower in the morphine group for 7·5 h (from 
1 h to 8·5 h after the clinical procedure; p=0·003; figure 4). 
Similarly, 1·5 h after the clinical procedure, oxygen 
saturation dropped by an average of 2% in infants 
allocated morphine, although this reduction was not 
significantly lower than in infants assigned placebo 
(figure 4). More than 12 h after the clinical procedure, 
oxygen saturation of infants allocated placebo dropped 
by 1·2%, and this value was significantly different to that 
for infants assigned morphine for 2 h (from 13 h to 15 h 
after the clinical procedure; p=0·022; figure 4). The 
appendix includes 48 h oxygen saturation and heart rate 
traces for all infants.
Discussion
This trial shows that administration of 100 μg/kg oral 
morphine before acutely painful clinical procedures in 
infants born prematurely (and aged 34–39 weeks’ 
gestation at study) has a profound negative effect on 
respiratory stability, without any suggestion of analgesic 
Onset of event 
post drug (h, min)
Treatment Grade Attribution Allocation
Adverse events
Nasal congestion 11 h, 56 min Saline drops Mild Not related Placebo
Rash 4 h, 4 min Cream Mild Not related Placebo
Profound desaturation episodes 17 h, 59 min Facial oxygen Mild Not related Placebo
Recurrent desaturation episodes 8 h, 9 min Stimulation Mild Possibly Morphine
Recurrent desaturation episodes 1 h, 58 min Facial oxygen Mild Possibly Morphine
Apnoea 2 h, 13 min NIPPV; increase high-flow oxygen Moderate Possibly Morphine
Recurrent apnoeic episodes 2 h, 39 min Stimulation; increase low-flow oxygen Moderate Possibly Morphine
Recurrent apnoeic episodes 1 h, 28 min Stimulation (× 3); NIPPV (× 3) Moderate Possibly Morphine
Recurrent desaturation, bradycardia, and apnoeic 
episodes
2 h, 3 min Commenced high-flow oxygen; feed volume reduction Moderate Possibly Morphine
Serious adverse events
Persistent hypoventilation and desaturation 6 h, 0 min Moved to high-dependency unit; commenced high-flow oxygen Moderate Possibly Morphine
Recurrent apnoeic episodes 6 h, 24 min Unmasked by clinical team; moved to high-dependency unit; 
commenced high-flow oxygen; naloxone (× 2)
Moderate Probably Morphine
Adverse events are shown that occurred during the 24 h period post administration of morphine or placebo. NIPPV=non-invasive positive pressure ventilation.
Table 3: Adverse events
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efficacy (video). A multimodal approach was used to 
assess analgesic efficacy and safety, providing detailed 
evidence of the effects of morphine on infant nociceptive 
and physiological activity. Behavioural pain scores, 
noxious­evoked brain activity, and reflex withdrawal 
activity did not differ between morphine and placebo 
groups. The study was under powered for the co­primary 
outcome measures, because of early trial cessation, and 
we therefore cannot conclude whether morphine 
provided effective analgesia at this dose. However, a 
trend was noted across modalities that infants who 
received morphine had greater noxious­evoked activity, 
suggest ing that even if the trial had continued to 
completion, we would have been unlikely to observe an 
analgesic effect of morphine.
This trial suggests that oral morphine at a dose of 
100 μg/kg in non­ventilated infants has the potential for 
harm. The profound respiratory effects observed justified 
trial cessation and lead us to recommend that oral 
morphine (at this dose) should not be given to non­
ventilated premature infants for acute pain relief during 
retinopathy of prematurity screening. The age range in 
this study was restricted to infants requiring retinopathy 
of prematurity screening at 34–42 weeks’ gestation, so we 
cannot ascertain the effects of oral morphine in younger 
or older infants. However, inter national paediatric 
formularies—eg, the British National Formulary for 
children—recommend an oral dose of 50–100 μg/kg every 
4 h in infants aged 1–2 months, and 50 µg/kg of 
intravenous morphine every 6 h to treat pain in neonates, 
which is roughly equivalent to the 100 µg/kg oral dose 
administered in this study, assuming an oral bio availability 
of approximately 50%.22 Our data suggest that in non­
ventilated premature infants of 1–2 months’ postnatal age, 
these doses could cause substantial respira tory adverse 
effects, requiring resuscitative respiratory support or 
a change in respiratory support modality. This effect 
might be due to immature glucuroni dation and reduced 
clearance of morphine metabolites, because these pro­
cesses are not mature in the first 2 months of life.23
Although an intravenous morphine dose of 10–30 µg/kg 
provided effective analgesia in infants receiving contin­
uous positive airway pressure in a previous study,24 severe 
apnoeic episodes requiring substantial intervention were 
reported in 9% of participants (who were very premature), 
and consistent with the findings of our study, a reduction 
in heart rate and respiratory rate was suggested. Similarly, 
a dose of 100 µg/kg of intravenous morphine in ventilated 
premature infants provided effective pain relief for central 
line placement in a previous study,25 but with significantly 
increased ventilation requirements com pared with 
infants who received tetracaine. Findings of another 
retrospective study16 showed that five of 43 infants who 
received approximately 50–100 µg/kg of intravenous 
morphine for central line placement had respiratory 
depression requiring inter vention or increased respiratory 
support, compared with none in a control group.
It is possible that if we had lowered the dose of oral 
morphine that the adverse respiratory outcomes could 
have been reduced. However, it seems unlikely that a lower 
dose would have provided effective analgesia. Although 
our national drug formulary recommends 50–100 µg/kg of 
morphine orally for pain, neonatal drug guidelines from 
other coun tries (eg, Australia) recommend higher oral 
doses of 100–200 µg/kg for pain in neonates.26 Our local 
practice guidelines also recommend that an oral dose of 
100 µg/kg is given to infants requiring laser eye surgery. In 
a pilot trial that was started but not completed,15 six non­
ventilated infants were administered a much larger oral 
dose of morphine (200 µg/kg) for retinopathy of 
prematurity screening. These researchers did not report 
any adverse effects. We therefore determined that, on 
balance, 100 µg/kg was a justifiable dose.
The acceptable balance of benefit and harm for any 
treatment is contextually dependent. All infants in our 
trial were clinically stable before the study started, and 
most infants who received morphine were cared for in a 
low­dependency setting and self­ventilating in air. 
Although ventilatory support can be routinely and expertly 
provided in neonatal care, escalation of oxygen therapy or 
level of care can be costly, result in prolongation of 
admission and distress to parents, and be viewed as a 
considerable setback. Ideally, morphine should be titrated 
to provide patients with optimum analgesic benefit and 
minimum adverse effects. The likely requirement for 
increased respiratory support would need to be expected, 
manageable, and justified by analgesic benefits. In our 
study, we noted considerable adverse effects before any 
suggestion of benefit, suggesting a non­existent thera­
peutic window in this context. Doses of morphine that 
are routinely administered intravenously to ventilated 
infants27 might provide effective analgesia in premature 
infants, albeit limited analgesic efficacy has been reported.3 
Because respiratory adverse effects can be managed well 
in ventilated infants, the benefit of morphine admini­
stration for sedation might outweigh the risks, and 
results from this study cannot be interpreted to suggest 
that ventilated infants should not be given morphine. 
Controversy remains over the analgesic efficacy of 
intravenous morphine for procedural pain in ventilated 
infants,3 and comprehensive assessment of pain­related 
brain activity could help settle this debate.
The single bolus dose of morphine administered in our 
trial produced clinically significant cardiorespiratory 
effects; the heart rate and respiratory rate were significantly 
lower in infants assigned morphine for 6–8 h after the 
clinical procedure. This finding corresponds with the half­
life of morphine in premature infants.28 A comparable 
degree of cardiorespiratory depression has been seen 
in ventilated infants receiving intravenous morphine 
infusions.29 This finding highlights the importance of 
comprehensively evaluating the side­effects of pain­
relieving drugs through detailed physiological recordings 
and clinical observations.
See Online for video
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Due to early trial cessation, our study was underpowered 
to detect significant effects in the co­primary outcome 
measures. Although mydriatic eye drops were given at 
approximately the same time as the drug, which might 
delay gastric emptying,30 this does not seem to have 
prevented morphine absorption. A limitation of our 
study design was that timing of peak analgesic efficacy of 
oral morphine is unknown; however, the time courses 
of cardiac and respiratory effects suggest a drug effect at 
the time of the clinical procedure. It is unlikely that 
an absence of analgesic efficacy is related to a lack of 
absorption or poor timing of drug administration.
In view of the challenges in measuring analgesic 
efficacy in non­verbal infants,31 the recorded increases in 
the measures of noxious­evoked brain activity, reflex 
withdrawal, and PIPP­R scores in response to the clinical 
procedure confirm the suitability of these approaches to 
assess analgesic efficacy. The multimodal approach used 
in our trial to assess both analgesic efficacy and drug 
safety can provide detailed mechanistic insight into the 
precise time course of physiological effects of potential 
analgesics. Although this multimodal methodology 
cannot be implemented easily into standard clinical 
practice, this work highlights the importance and 
feasibility of using this approach in future clinical trials 
of analgesics in infants.31
Our trial provides further evidence that retinopathy of 
prematurity screening is a painful and destabilising 
procedure. In a meta­analysis of pain relief for retinopathy 
of prematurity screening,32 with topical anaesthetic the 
median PIPP score was 15, reducing to 11 with the addition 
of sweet taste. In our placebo group, the mean PIPP­R 
score was 10·5, and 20% of infants developed new­onset or 
increased apnoeic episodes in the 24 h after the clinical 
procedure. This finding corresponds with previous work7,8 
and provides further evidence that pain during retinopathy 
of prematurity screening is not being managed adequately 
in clinical practice. Post­procedure monitoring require­
ments should be considered carefully, particularly in 
infants who require retinopathy of prematurity screening 
after discharge in an outpatient setting. Novel imaging 
techniques for retinopathy of prematurity screening are 
being developed but are currently used as an adjunct to 
indirect ophthalmoscopy rather than as a replacement.33 
Further clinical trials should be done to identify effective 
analgesia for this procedure.
In conclusion, oral morphine at a dose of 100 μg/kg has 
the potential for harm with no suggestion that it provides 
analgesic efficacy for acute clinical procedures in non­
ventilated infants born prematurely (and aged 
34–39 weeks’ gestation at study). However, because of 
early trial cessation, we cannot draw conclusions about 
the analgesic efficacy of oral morphine; obtaining a large 
enough sample size to test this objective would have 
required exposing infants to an unacceptable risk of 
respiratory adverse events. We do not recommend this 
dose of morphine for use as pain relief during binocular 
indirect ophthalmoscopy retinopathy of prematurity 
screening. Using multimodal outcome measures, along 
with detailed physiological recordings, provides a 
rigorous approach to assess analgesic efficacy and adverse 
effects, leading to a greater mechanistic understanding of 
the effects of a drug, and is desirable in future clinical 
trials of analgesics in infants.
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